Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women

• Published in: Contraception (Stoneham) 1999-10, Vol.60 (4), p.189-200
• Main Authors: Rahimy, Mohamad H, Ryan, Kristi K
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Birth control; Contraceptive Agents, Female - administration & dosage; Contraceptive Agents, Female - pharmacokinetics; Estradiol - administration & dosage; Estradiol - analogs & derivatives; Estradiol - blood; Estradiol - pharmacokinetics; estradiol cypionate; Female; Gynecology. Andrology. Obstetrics; Hormonal contraception; Humans; Injections, Intramuscular; Kinetics; Lune; Lunella; Lunelle; Medical sciences; medroxyprogesterone acetate; Medroxyprogesterone Acetate - administration & dosage; Medroxyprogesterone Acetate - pharmacokinetics; monthly contraceptive injection; MPA/E 2C; Ovulation; pharmacodynamics; Population; progesterone; Progesterone - blood; return of ovulation; Sterilization, Tubal
• ISSN: 0010-7824; 1879-0518
• DOI: 10.1016/S0010-7824(99)00081-5

The pharmacodynamic effects of medroxyprogesterone acetate (MPA) and estradiol cypionate (E 2C) (MPA/E 2C) (Lunelle™ Monthly Contraceptive Injection) on ovarian function were assessed through changes in serum progesterone concentrations. The data described here were obtained simultaneously with pharmacokinetic data presented in another article in this issue. Sixteen surgically sterile women with regular menstrual cycles were studied for one control cycle, three consecutive treatment months, and 3–5 months of follow-up. Suppression, followed by resumption of ovulation (the dynamic end point), was assessed by serum progesterone levels. Return of ovulation was presumptive based on progesterone concentrations ≥4.7 ng/mL, as ultrasound was not used to determine the follicular/ovulatory status of these subjects. Luteal-like serum progesterone peaks were observed in all 16 women before drug administration, confirming the presence of ovulatory cycles. After the third monthly injection of MPA/E 2C, progesterone concentrations were measured until demonstration of ovulation. Two women discontinued and three were lost to follow-up before this objective was achieved. Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks (serum progesterone concentrations did not exceed 1 ng/mL). The first normal ovulatory cycle, based on progesterone concentrations ≥4.7 ng/mL, was observed in 11 women between days 63 and 112 after the third injection. Select medroxyprogesterone acetate parameters (i.e., area under the curve and minimum concentration) were correlated with return of ovulation. The correlation coefficients (r) were 0.757 and 0.492 for area under the curve and minimum concentration, respectively, indicating that return of ovulation is dependent, in part, on area under the curve and on the magnitude of the serum MPA trough level. In general, the higher the minimum concentration levels, the longer the time to return of ovulation. In conclusion, the return of ovulation, as confirmed by serum progesterone concentrations ≥4.7 ng/mL, was observed as early as 63 days after the third and final monthly intramuscular injection of MPA/E 2C, suggesting that consistent suppression of the hypothalamic-pituitary-ovarian axis is reversible after discontinuation of dosing.